Kathryn E Falberg Trade Desk, Inc. (TTD) insider trading activity

Kathryn E Falberg is Director of Trade Desk, Inc.. Currently has a direct ownership of 104,774 shares of TTD, which is worth approximately $9.03 Million. The most recent transaction as insider was on May 27, 2025, when has been sold 7,774 shares (Class A Common Stock) at a price of $44.38 per share, resulting in proceeds of $345,010. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 105K

8.01% 3M change

57.57% 12M change

Total Value Held $9.03 Million

KATHRYN E FALBERG Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
May 27 2025	BUY Grant, award, or other acquisition	$345,010 $44.38 p/Share	7,774 Added 6.91%	104,774 Class A Common Stock
Apr 15 2025	BUY Grant, award, or other acquisition	$5,735 $63.73 p/Share	90 Added 0.09%	97,000 Class A Common Stock
Aug 13 2024	SELL Open market or private sale	$14,725,500 $98.17 p/Share	150,000 Reduced 60.75%	96,910 Class A Common Stock
May 28 2024	BUY Grant, award, or other acquisition	$249,931 $58.11 p/Share	4,301 Added 1.71%	246,910 Class A Common Stock
Mar 08 2024	SELL Open market or private sale	$8,461,853 $82.13 p/Share	103,030 Reduced 29.81%	242,609 Class A Common Stock
Mar 08 2024	BUY Conversion of derivative security	$185,454 $1.8 p/Share	103,030 Added 22.96%	345,639 Class A Common Stock
May 25 2023	BUY Grant, award, or other acquisition	$243,244 $41.68 p/Share	5,836 Added 2.35%	242,609 Class A Common Stock
Feb 06 2023	SELL Sale (or disposition) back to the issuer	$1,256 $59.83 p/Share	21 Reduced 0.01%	236,752 Class A Common Stock
May 26 2022	BUY Grant, award, or other acquisition	$240,638 $44.87 p/Share	5,363 Added 2.21%	236,773 Class A Common Stock
May 27 2021	BUY Grant, award, or other acquisition	$239,870 $479.74 p/Share	500 Added 13.73%	3,141 Class A Common Stock
Nov 19 2020	SELL Open market or private sale	$16,273,199 $813.66 p/Share	20,000 Reduced 88.34%	2,641 Class A Common Stock
Nov 19 2020	BUY Conversion of derivative security	-	20,000 Added 46.9%	22,641 Class A Common Stock

Also insider at

NUVB

Nuvation Bio Inc. Healthcare

RCUS

Arcus Biosciences, Inc. Healthcare

Director

URGN

UroGen Pharma Ltd. Healthcare

Director

TCDA

Tricida, Inc. Healthcare

Director

KEF